Metfogama is used to control blood sugar levels in type II diabetes. It can also be used in children from 10 years of age, including those with excess body weight, if diet therapy and physical activity are ineffective. It can be used in combination with insulin, subject to regular monitoring of blood sugar levels, in order to avoid an attack of hypoglycemia.
active substance: metformin;
1 tablet contains metformin hydrochloride 500 mg;
Excipients: povidone, magnesium stearate.
This drug Metfogama belongs to a group of drugs that affect digestion and metabolic processes in the body, antidiabetic agents.
The main active ingredient is metformin. It belongs to the group of biguanides that lower blood sugar levels in non-insulin dependent type II diabetes. Reliably reduces mortality in this disease.
It is also used for polycystic ovary disease, obesity.
The mechanism of action is the ability to inhibit the synthesis of glucose by liver cells by one third. It is also able to increase the amount of cytosolic adenosine monophosphate.
Inhibits the respiratory complex I. By suppressing gluconeogenesis in the liver, increases the susceptibility of body cells to insulin, increases lipid oxidation, reducing the absorption of glucose from the gastrointestinal tract.
It increases blood circulation in the liver cells, promoting the conversion of glucose into glycogen. Decreased appetite from metformin supplementation promotes low-carb diet therapy.
Metfogama is used to control blood sugar levels in type II diabetes.
It can also be used in children from 10 years of age, including those with excess body weight, if diet therapy and physical activity are ineffective.
It can be used in combination with insulin, subject to regular monitoring of blood sugar levels, in order to avoid an attack of hypoglycemia.
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or one of the auxiliary components.
Also contraindicated for:
- eating less than 1,000 kilocalories per day;
- type I diabetes mellitus (insulin dependent);
- will have no effect on completely stopping insulin production in type II diabetes;
- symptoms of diabetic ketoacidosis, diabetic precoma, coma;
- myocardial infarction, heart failure;
- severe infections, impaired liver and kidney function;
- lung diseases, operations and injuries;
- catabolic diseases, the presence of tumors of various etiologies;
It should be borne in mind that Metfogama reduces its effectiveness when taking thyroid hormones, using oral contraception, diuretics, glucocorticoids.
In pediatrics, it has been used since 10 years.
Application during pregnancy and lactation
This drug is not used for the treatment of women and during lactation.
Method of administration and dosage
Metfogama is administered orally (by mouth) during or after meals.
The starting dose is 500 mg 2-3 times a day.
After 10-15 days, the dose is adjusted according to the results of the glycemic profile.
The maximum recommended dose is 3000 mg per day, divided into 3 doses.
The initial dose for children over 10 years old is 500 mg once a day, the maximum dose is 2000 mg / day, divided into 2-3 doses.
An overdose can cause an attack of hypoglycemia, which can result in a coma (a sharp drop in blood glucose levels to a critical level). Symptoms of hypoglycemia: tachycardia, trembling in the limbs, increased sweating, blurred consciousness. In this case, immediately give the patient a sugar solution, in case the patient has lost consciousness, inject a glucose solution intravenously. After regaining consciousness, feed the patient with food with a high glycemic index.
It is also possible to develop lactic acidosis, the symptoms of which are nausea, vomiting, weakness, rapid breathing, muscle pain, loss of consciousness.
The development of hypoglycemia and lactic acidosis increases with the simultaneous intake of alcohol.
In some cases, side effects such as:
- dyspeptic disorders (nausea, vomiting, diarrhea);
- allergic reactions, rash, itching, allergic urticaria;
- dysgeusia, taste disturbances;
- loss or decrease in appetite;
- hepatitis, liver dysfunction (disappear after drug withdrawal).
Storage conditions and periods
Expiration date – 5 years from the date of manufacture indicated on the package.
The storage temperature should not exceed 25 ° C.